Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride - Generic Drug Details

What are the generic sources for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride and what is the scope of freedom to operate?

Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

B01AB	Heparin group
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

C01BB	Antiarrhythmics, class Ib
C01B	ANTIARRHYTHMICS, CLASS I AND III
C01	CARDIAC THERAPY
C	Cardiovascular system

C05AD	Local anesthetics
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

C05BA	Heparins or heparinoids for topical use
C05B	ANTIVARICOSE THERAPY
C05	VASOPROTECTIVES
C	Cardiovascular system

D04AB	Anesthetics for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

N02CA	Ergot alkaloids
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

N02CA	Ergot alkaloids
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

R02AD	Anesthetics, local
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01HA	Local anesthetics
S01H	LOCAL ANESTHETICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02DA	Analgesics and anesthetics
S02D	OTHER OTOLOGICALS
S02	OTOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-002	Nov 30, 1984		DISCN	No	No
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984		DISCN	No	No

Expired US Patents for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-002	Nov 30, 1984
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-002	Nov 30, 1984

Market dynamics and financial trajectory for dihydroergotamine mesylate, heparin sodium, and lidocaine hydrochloride

Last updated: February 15, 2026

What are the current market sizes and growth rates for dihydroergotamine mesylate, heparin sodium, and lidocaine hydrochloride?

Dihydroergotamine mesylate (DHE):

• Estimated global market in 2022 was approximately $500 million.
• Projected compound annual growth rate (CAGR) from 2023 to 2030 is 3-4%.
• Growth driven by its use in migraine management and limited competition due to patent expiration.

Heparin sodium:

• Global market reached around $2.5 billion in 2022.
• CAGR estimated at 5-6% over the next eight years.
• Driven by increasing surgical procedures, thrombosis treatments, and rising hospital admissions.

Lidocaine hydrochloride:

• Market size estimated at $1.2 billion in 2022.
• CAGR projected at 4-5% from 2023 to 2030.
• Growth propelled by its widespread usage in anesthesia, cardiac arrhythmia management, and pain relief.

How are patent statuses, generics, and regulatory policies affecting these drugs' market trajectories?

• Dihydroergotamine mesylate:

  • Patent expired in the U.S. in 2002; several generics available.
  • Limited new formulation development; growth relies on existing indications.
  • FDA approval barriers are moderate; off-label uses are common in some regions.

• Heparin sodium:

  • As an established drug, patents have long expired.
  • Market dominated by generics; price sensitivity influences revenue.
  • Regulatory standards for manufacturing and safety (e.g., contamination risks) are high.

• Lidocaine hydrochloride:

  • Patent expired decades ago; high generic competition.
  • Regulatory policies focus on formulation stability, preservative use, and delivery methods.
  • Innovations such as controlled-release formulations face obstacles due to rigorous approval processes.

What are the key drivers, challenges, and competitive trends influencing these markets?

Drivers:

• Growing prevalence of migraines increases demand for DHE.
• Surge in surgical and hospitalization rates fuels heparin use.
• Expanding use of lidocaine in pain management and anesthesia.

Challenges:

• Price erosion due to generic competition shrinks profit margins.
• Regulatory and safety concerns ([1]) for heparin, especially related to contamination crises, influence market stability.
• Stagnation in formulation innovation limits market expansion for all three drugs.

Competitive trends:

• Companies optimize manufacturing efficiencies to reduce costs.
• Development of new delivery systems, such as patches or injectables, aims to differentiate products.
• Strategic acquisitions focus on newer formulations or combination therapies to extend lifecycle.

What is the financial outlook based on recent patent and regulatory trends?

Drug	2022 Revenue (USD)	Forecast CAGR (2023–2030)	Key Factors
Dihydroergotamine mesylate	$500 million	3-4%	Mature market, limited innovation, utilization dependent on migraine prevalence
Heparin sodium	$2.5 billion	5-6%	High volume, price sensitivity, regulatory scrutiny, impact of contamination scandals ([2])
Lidocaine hydrochloride	$1.2 billion	4-5%	Ubiquitous use, price competition, slow innovation, opportunities in alternative delivery systems ([3])

Investment implications:

• Stable cash flow for companies with established market share, especially in heparin.
• Opportunities exist in developing novel formulations or improved delivery mechanisms for lidocaine.
• Risks involve regulatory setbacks, patent limitations, and pricing pressures.

Key Takeaways

• The market for dihydroergotamine mesylate remains mature with steady, modest growth, primarily driven by migraine treatment needs.
• Heparin sodium maintains significant revenue; growth stems from procedural volume increases but faces regulatory scrutiny and price competition.
• Lidocaine hydrochloride benefits from broad application but sees slow innovation; growth depends on new delivery systems and formulation improvements.
• Patent expirations have led to generic proliferation, reducing prices but maintaining market size due to consistent demand.
• Regulatory challenges, especially for heparin, will influence market stability and innovation pathways.

FAQs

1. What factors could accelerate growth for these drugs?
Emerging formulations that improve delivery, reduce side effects, or provide new therapeutic indications can boost growth.

2. How does regulatory environment impact these markets?
Stringent safety standards, especially for heparin, can delay new formulations and impose costs but ensure product safety and sustain market trust.

3. Are biosimilars influencing the heparin market?
Yes, biosimilars are entering the market, increasing competition and further pressuring prices.

4. What is the main barrier to innovation in these markets?
High regulatory hurdles and the established nature of these drugs limit innovative development.

5. How have recent safety scandals affected the heparin market?
They have led to increased quality controls and regulatory oversight, potentially increasing costs but enhancing product safety.

---

References:
[1] U.S. FDA. Hemodialysis-Related Contaminated Heparin. 2012.
[2] The New York Times. F.D.A. Asserts Crooked Practices in Heparin Production. 2008.
[3] Markets and Markets. Lidocaine Market by Formulation, Application, and Region. 2023.